New Benefits Give SGLT2 Inhibitors Their Turn to Shine - Frankly Speaking Ep 376
Apr 15, 2024•8 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Credits: 0.25 AMA PRA Category 1 Credit™
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-376
Overview: While GLP-1 agents are center stage in the medical and lay press, drugs in the class of sodium-glucose cotransporter 2 inhibitors (SGLT2is) are also quite remarkable at improving a variety of health endpoints. This episode provides an overview of studies supporting the use of SGLT2is to improve patient outcomes.
Episode resource links:
- DM/HF: Age Ageing 2024 Jan 2;53(1):afad254. doi: 10.1093/ageing/afad254
- Kidney stones: JAMA Intern Med. 2024 Jan 29:e237660. doi: 10.1001/jamainternmed.2023.7660
Guest: Susan Feeney, DNP, FNP-BC, NP-C
Music Credit: Richard Onorato
For the best experience, listen in Metacast app for iOS or Android